Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 18Terminated 5Unknown 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Leukemia, Myeloid, Acute 18Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Monocytic, Acute 6Prostatic Neoplasms 5Leukemia, Myelomonocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Leukemia 5Congenital Abnormalities 4Lymphoma, Follicular 3Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Eosinophilic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Mitoxantrone × Clear all
NCT01522443 2018-05-23

COMET-2

Exelixis

Phase 3 Terminated
119 enrolled 21 charts
Genitourinary

Pain, Prostatic Neoplasms

NCT00477087 2017-11-29

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Stanford University

Phase 2 Terminated
10 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00447473 2016-03-17

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
31 enrolled
Genitourinary

Prostatic Neoplasms

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Centocor, Inc.

Phase 2 Terminated
106 enrolled 13 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00452387 2011-09-16

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Accelerated Community Oncology Research Network

Phase 2 Terminated
22 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡